1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 1:Demographic and clinical characteristics
Study Group Control Group P Value No. 29 15 Sex, M/F 10/19 11/4 .03 Age, y 46.4 ± 9.5 42.6 ± 7.1 .18 Disease duration, y 12.6 ± 6.7 NA Disease course (RR/SP/PP) 17/8/4 NA EDSS 3.6 ± 2.1 (1.0–7.0) NA
Note:—NA indicates not applicable; RR, relapsing-remitting; SP, secondary-progressive; PP, primary-progressive.